P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
H. Quach,
X. Leleu,
M.-V. Mateos,
S. Z. Usmani,
A. K. Nooka,
A. Goldrick,
R. Najdi,
N. Shu,
T. Facon
Affiliations
H. Quach
1 University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia
X. Leleu
2 CHU de Poitiers, La Miletrie/INSERM CIC 1402, Poitiers, France
M.-V. Mateos
3 University Hospital Salamanca/ISAL, Salamanca, Spain
S. Z. Usmani
4 Memorial Sloan Kettering Cancer Center, New York
A. K. Nooka
5 Winship Cancer Institute, Emory University, Atlanta
